News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Khalil Choucair: Potential biomarkers of IO-therapy in patients of extremes of age
Khalil Choucair/LinkedIn
Jan 19, 2025, 14:12

Khalil Choucair: Potential biomarkers of IO-therapy in patients of extremes of age

Khalil Choucair, Chief Fellow of Hematology & Oncology at Karmanos Cancer Institute, reshared a post by BMJ Oncology on LinkedIn, adding: 

“Our work exploring potential biomarkers of IO-therapy in patients of extremes of age, is now published in BMJ Oncology.”

Quoting BMJ Oncology‘s post:

“Participation of older patients in immune checkpoint inhibitors trials has been suboptimal, particularly at the extremes of age.”

Khalil Choucair: Potential biomarkers of IO-therapy in patients of extremes of age

Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma.

Authors: Khalil Choucair, et al.

Khalil Choucair: Potential biomarkers of IO-therapy in patients of extremes of age

BMJ Oncology cancer fight against cancer Global fight against cancer Hematology Karmanos Cancer Institute Khalil Choucair non small cell lung cancer NSCLC OncoDaily Oncology
Special Coverage
Insight
Jan 19, 2025, 14:12
Olubukola Ayodele: Breaking the Culture of Silence: Addressing Health Inequities in Black Communities
Science
Jan 19, 2025, 14:12
Khalil Choucair: Potential biomarkers of IO-therapy in patients of extremes of age
Insight
Jan 19, 2025, 14:08
Karen Knudsen: What if your grocery list could help lower your cancer risk?
Science
Jan 19, 2025, 14:08
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Insight
Jan 19, 2025, 14:07
Aleix Prat: Utility of the HER2DX genomic assay in predicting pCR in HER2+ stage III IBC
Insight
Jan 19, 2025, 14:02
Cristina L.: Anti-GD2 Immunotherapy in retinoblastoma
Blog
Jan 19, 2025, 13:58
Douglas Flora: Making a real difference in cancer care delivery across the nation
Insight
Jan 19, 2025, 13:52
Amol Akhade: Datopotomab deruxtecan got approved for HR+ HER2- MBC in the third line
Insight
Jan 19, 2025, 13:47
Amy Moore: Are patients with RET+ NSCLC on TKIs protected against cachexia?
Blog
Jan 19, 2025, 13:44
Mary Feng: ASCOGI25 starts next week
Science
Jan 19, 2025, 13:39
KRAS Mutation Status and Treatment Outcomes in Patients with Metastatic Pancreatic Adenocarcinoma
Blog
Jan 19, 2025, 13:32
SWOG Cancer Research Network - One Form to "Rule" Them All